🇺🇸 TOCAINIDE HYDROCHLORIDE in United States

FDA authorised TOCAINIDE HYDROCHLORIDE on 9 November 1984 · 10 US adverse-event reports

Marketing authorisations

FDA — authorised 9 November 1984

  • Application: NDA018257
  • Marketing authorisation holder: ASTRAZENECA
  • Local brand name: TONOCARD
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Aneurysm — 1 report (10%)
  2. Aortic Valve Disease — 1 report (10%)
  3. Arrhythmia — 1 report (10%)
  4. Blood Triglycerides Increased — 1 report (10%)
  5. Coronary Artery Occlusion — 1 report (10%)
  6. Deformity — 1 report (10%)
  7. Drug Ineffective — 1 report (10%)
  8. Dry Skin — 1 report (10%)
  9. Emotional Distress — 1 report (10%)
  10. General Physical Health Deterioration — 1 report (10%)

Source database →

TOCAINIDE HYDROCHLORIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TOCAINIDE HYDROCHLORIDE approved in United States?

Yes. FDA authorised it on 9 November 1984; FDA has authorised it.

Who is the marketing authorisation holder for TOCAINIDE HYDROCHLORIDE in United States?

ASTRAZENECA holds the US marketing authorisation.